the 6' nitrogen atom of the drug by the enzyme kanamycin 6'-acetyltransferase (EC 2.3.1.55). The transfer, stoichiometric and quantitative, is complete after 10-mm incubation at 37 #{176}C. The labeled acetylaminoglycoside is adsorbed onto phosphocellulose paper discs, which are washed to remove any unreacted ['4C]acetyl-coenzyme A. The radioactivity is then eluted into liquid scintillation counting vials and counted for 1 mm each. The assay detects as little as 2 ng of either drug and the standard curve is linear into the toxic range of concentrations. Most of the commonly administered aminoglycosides act as substrates in the assay, except for the C component of gentamicin C complex. Neither hemolysis, lipemia, nor icterus interfere with the assay. Results compare favorably with those determined by radioimmunoassay and a microbiological method.
Additional Keyphrases The bactericidal effect of the aminoglycosides is lost below a minimum dosage (1-3), while their toxicity places an upper limit on the therapeutically useful concentration (4) (5) (6) (7) . A rapid and sensitive test for determining the concentration in plasma or serum is needed for safe and effective treatment with these drugs because of the narrow range of concentrations that are effective without being toxic. Current methods for determining aminoglycosides have recently been reviewed (8) . Three of them account for most of current testing, although some newer methods are also being developed.
The advantages and drawbacks of these newer methods are well described in the review, and only the three major methods will be evaluated here. The agar diffusion (microbiological) method requires inexpensive materials, but is slow, less precise than alternative procedures, and is subject to interference by other antibiotics. are nonlinear and require several standards. Enzymic methods inwhich an enzyme is used to label the drug with radioactivity are linear, rapid,sensitive, and highly specific (9) (10) (11) (12) .
In the assay presented here, the commercially-available enzyme kanamycin 6'-acetyltransferase (KAT, EC 2.3.1.55) is used, which catalyzes the reaction:
The use of [1-'4C)acetyl-coenzyme A in the reaction produces a radiolabeled aminoglycoside, which can then be separated and quantitated. and dispensed in 50-tL aliquots into the reaction tubes. All solutions were kept on ice during the preparation.
Methods and Materials
In the tobramycin procedure, the reaction was started by adding 10 zL of specimen or standard to the working solution and vortex-mixing.
The tube was then placed in a 37 #{176}C water bath for 10 mm, after which a 50-ML sample was withdrawn and adsorbed to a phosphocellulose disc suspended on a pin above the polystyrene mounting board. After a 1-mm adsorption period, the discs were dropped into a beaker of distilled water and washed by soaking for 2 mm, after which the water was decanted.
This washing operation was repeated twice. The discs were then transferred to an absorbent paper towel and blotted dry before being placed into individual liquid-scintillation counting vials. One-half milliliter of 1.4 mol/L ammonium hydroxide was added to each vial, to thoroughly saturate the phosphocellulose disc. Two minutes later 10 mL of ACS#{174} scintillation cocktail were added. The contents of the vials were mixed, allowed to cool in the scintillation counter for 30 mm, and then counted for 1 mm each. For these studies, we used a Packard Model 3320 liquid-scintillation counter.
In the initial amikacin work, the procedure was identical to that described for tobramycin. However, for most of the work reported here, we reduced the size of the sample aliquot to 5 tL. This change was necessary to extend the linearity of the assay into the toxic range for amikacin without requiring dilution of the specimens. Except for this change in volume, the amikacin procedure is identical to the tobramycin procedure given above.
Results and Discussion

Reaction Conditions
Initially, it was of interest to determine if the Gentamicin E.R.ATM kit could be modified to assay tobramycin and amikacin in human serum by simply substituting the KAT enzyme for GAT I and using all other components as supplied. When KAT is used in an activity comparable to that of GAT I in the kit, the standard curves for both tobramycin and amikacin are linear to a concentration of at least 20 mg/L. The curve for gentamicin C complex is also linear to 20 mg/L, but the observed counts per minute are lower because gentamicin C1 fails to react in the assay. As shown in Figure 1 , the acety-
:. lation reaction is essentially complete after 5 mm; a 10-mm incubation assures completion of the reaction. The stability of the reaction products is also apparent in Figure 1 ; the adsorbed radioactivity is constant from 10 mm to at least 30 mm, and shows no evidence of degradation of the labeled acetylaminoglycoside product.
Because the optimum pH for the KAT enzyme with kanamycin is reported (9) to be 5.7 rather than the 7.5 of the kit buffer, we varied the pH of the reaction mixture to ascertain the pH optimum. With the enzyme as the limiting factor in the assay and the substrate in excess, we did find the pH optimum to be near 5.7 with each of the aminoglycosides tested. However, when we repeated the experiment, using the usual drug assay conditions, where substrate is the limiting factor, we observed a different pH profile: radioactivity incorporated during the 10-mm incubation then showed a broad maximum, centered around pH 7.5 for both tobramycin and amikacin.
Thus the pH of the buffer in the reagent set is indeed optimal for assay of these drugs.
The overall conclusion of these studies on reaction conditions is that when KAT is substituted in the Gentamicin E.R.A'M kit for GAT I on an equal-activity basis, the resulting conditions are suitable for assay of tobramycin and amikacin. However, amikacin is administered in larger doses than either gentamicin or tobramycin, and its therapeutic range is about double that of these drugs (8) . We find that merely decreasing the sample size to 5 L extends the assay range to beyond 40 mg/L, while maintaining good precision (see Performance Characteristics below). For the remainder of the work, we used 10-L samples for tobramycin assays and 5-1zL samples for amikacin assays.
Performance Characteristics
Precision. Four specimens were prepared to test the within-run and day-to-day precision of the procedure. Two specimens of tobramycin and two of amikacin were prepared by supplementing aminoglycoside-free serum with a concentrated aqueous solution of the respective drug. The concentration of one specimen of each drug was in the midtherapeutic range, the other in the toxic range. Each of the four serum specimens was assayed 16 times in a single run, then reassayed in duplicate each day for 10 additional days. Means (X), standard deviations (SD), and coefficients of variation (CV) were calculated. Observed CVs were in all cases <6%, a degree of precision that compares favorably with that claimed for RIA procedures and is much better than that obtainable by microbiological procedures. The CVs are nearly constant over the entire range of the assay (Table 1 Table 2 were prepared and analyzed according to the assay protocol. Table  2 lists the percent recovery for each specimen;
the average recovery, 99.4%, was not statistically different from 100%.
In addition, several commercially available control sera for the aminoglycoside drugs were analyzed in this system. The calculated concentrations are within the manufacturer's control range for all sera tested except for the low-concentration amikacin, the highest concentration of kanamycin, and all concentrations of gentamicin ( Table 3 ). The discrepancy in both amikacin and kanamycin is small (about 3%). This reagent set is not recommended for gentamicin because of the nonreactivity of gentamicin C1 (9) (see Specificity below and We therefore consider the precision and sensitivity obtained with this procedure to be completely satisfactory. 
Range.
Radioactivity incorporated during the assay is shown in Figure 2 as a function of tobrarnycmn concentration.
The standard curve is linear up to at least 20mg of tobramycin per liter, as is that for amikacin up to at least 40 mg/L when the protocol described above was used. An excellent direct relationship exists up to the highest concentrations studied, even though the highest tobramycmn concentration is beyond the linear range of the assay.
Specificity. Figure 3 shows the structure of tobrainycin and amikacin and of the components of the gentamicin C complex.
KAT is a broad-spectrum acetylating enzyme, which acts on any ammnoglycoside antibiotic that has a primary nitrogen atom at the 6' position (R2 = H, see Figure 3 ).
To assess the reactivity of each of the drugs in the assay, we prepared serum specimens containing 10 and 20 mg of the aminoglycosides kanamycin, gentamicin C complex, tobramycin, amikacin, and netilmicin per liter, along with similar specimens containing neomycin and streptomycin. Each of these specimens was assayed in triplicate by the procedure for tobramycmn.
The results are reported in Table 4 . Analytical recoveries for kanamycin, sisomicin, and netilmicin are 100%, within the precision of the assay. Amikacin recovery is also 100% after correction for molecular mass. Neomycin is slightly less reactive in this assay; about 90% of this drug is accounted for analytically when correction for molecular mass is made.
The possibility of interference by other antibiotics was also studied. Sera were prepared containing the highest clinically were determined from the amikacin standard curve. 11): cephalothin, chloramphenicol, clindamycin, nafcillin, spectinomycin, and tetracycline. Each solution was then assayed by both the tobramycin protocol and the amikacin protocol. Tobramycin was added to an aliquot of each serum to give a concentration of 20 mg/L, and the supplemented sera were assayed for tobramycin. Separate aliquots of sera were similarly supplemented with amikacin and re-assayed.
R3
The results indicate no significant interference by any of the drugs tested.
We conclude that the assay is highly specific for aminoglycosides as a class. The only aminoglycosides that failed to react are gentamicin C1 and streptomycin, both of which have a substituent group on the 6'-nitrogen of the drug (see Figure  3) . That a broad spectrum of aminoglycosides is active in this assay is advantageous for two reasons. The first is the obvious convenience for the laboratory that comes with being able to use identical reagents for several procedures (13) . The second may be of clinical importance, because concurrent administration of two aminoglycosides can lead to synergistic toxicity. In those patients with compromised renal function for whom a change in the drug to be administered is indicated, the drug initially given conceivably might not be cleared before the new aminoglycoside is started. In such cases, the E.R-A method with use of KAT will give a higher concentration of drug than expected after the initial dose of the new drug, whereas the residual drug would remain undetected in any assay specific for the newly started drug. Thus, the E.R.A method has a potentialadvantage over both the microbiological assay,with which non-aminoglycoside drugs frequentlyinterfere, and the RIA assays,which are specificfor a singleaminoglycoside moiety.
In addition, we investigated the possibility of interference from lipemia, icterus, and hemoglobin.
We prepared 2 and 20 mgIL standards of each ammnoglycoside in a matrix of abnormal control serum. In addition, we added pure substances to portions of each standard to obtain the concentrations of triglycerides, bilirubin, and hemoglobin indicated in Table  5 as can be seen in Table 5 .
Method-Comparison Study
As a part of the clinical evaluation of the procedure, our E.R.A method for tobramycin and amikacin was compared 
Reagent Stability
Two types of stability studies were set up on each of the reagent components that had not been previously tested: long-term stability studies under recommended storage conditions, and studies of stability at increased temperatures. None of the components as supplied deteriorated significantly when stored at 4 #{176}C for at least six months. The lyophilized tobramycin and amikacin standard materials were stable for six months, even when stored at 56 #{176}C, as was the enzyme when stored at ambient temperatures (18-25 #{176}C). The shelflife of this reagent set depends on the stability of the reconstituted standard solutions, which are stable for at least six months at 4 #{176}C. This compares quite favorably with the shelf-life of most RIA kits, which is limited to about two months by the half-life of 125!.
In addition, we carried out stability experiments on the working standards used in the assay. No measurable decrease in potency was found after storage for one month at 4 #{176}C, or after at least two months at -20 #{176}C. This suggests that patients' specimens can be stored for at least two weeks at 4 #{176}C without deterioration, and that working calibration solutions as well as quality-control specimens can be stored frozen and validly used for at least two months after they are pre-H pared.
The stability of the complete reaction cocktail was also assessed. The premixed reagent was found to be fully active after 48 h on ice. Reaction cocktail stored at either -20 or -70 #{176}C was fully active after six weeks. Standard curves run after the mixture had been stored for three months at -20 #{176}C were linear only up to 10 mg tobramycin per liter and 20 mg amikacin per liter; when stored at -70 #{176}C, no deterioration was observed even after three months. The stability of the premixed cocktail shows that reagent sufficient for at least one month may be prepared, dispensed, and stored at -20 #{176}C, or for three months if the aliquots are stored at -70 #{176}C. In either case, predispensed tubes provide a convenient source of reaction cocktail for a period of time longer than one working day, and minimize the steps required to set up a batch of assays on any given day.
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The materials necessary for the assay are commercially available. The standard curve for the assay is linear throughout the therapeutic range for both tobramycin and amikacin,and intotheirrespective toxicranges.The precision of the assay is largely independent of the concentration of the drug, and the shelf-life of the component reagents is at least three times that of most RIA kits. The assay distinguishes concentration differences of as little as 0.5 mg of tobramycin or amikacin per liter throughout the range, and is highly specific for aminoglycosides as a class. No interference was found from other antibiotic drugs commonly administered with an aminoglycoside, or from abnormal concentrations of bilirubin or triglycerides or from even moderate hemolysis of the specimen.
Finally, results by the method presented here and both of the common alternative methods-microbiological susceptibility and RIA-correlate well (r >0.80). We believe, therefore, that this enzymic radiochemical assay is an acceptable and useful method for use in the clinical laboratory.
